
Waters™

Application Note

An Integrated LC-MS Workflow with ProMass HR for Synthetic Peptide Impurity Analysis

Ximo Zhang, William R. Alley, Robert E. Birdsall, Ying Qing Yu

Waters Corporation



This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This work demonstrates that incorporating ProMass HR in MassLynx Software data processing can be used for synthetic peptide impurity analysis.

Benefits

High-resolution characterization of synthetic peptide impurities using MassLynx Software and ProMass HR.

Introduction

The potential for therapeutic peptides as personalized vaccines has been demonstrated with the recent successful adjuvant treatment of melanoma. However, impurities introduced through the synthetic process or degradation of the peptide can impact the efficacy and consistency of the drug product, making it critical to characterize and monitor the impurity profiles of synthetic peptides for drug development and quality control. Mass spectrometry (MS) is a commonly used platform in pharmaceutical development for structural characterization, molecular weight confirmation, and impurity analysis. Workflows that are intuitive and can be automated are an effective means to assist the processing and interpretation of complex MS-based data enabling biopharmaceutical companies to bring life-saving drug products to market faster with increased confidence in product quality.

Results and Discussion

In this study, we used a Waters Xevo G2-XS QTof MS coupled with an ACQUITY UPLC H-Class Bio System and a TUV Detector for high-mass resolution synthetic peptide impurity profiling. The software ProMass HR (by Novatia) for MassLynx Software serves as an automated data processing platform for MS spectral deconvolution, impurity analysis, and reporting.² A synthetic peptide, eledoisin (purchased from New England Peptide), was selected as a model analyte for its clinical relevance. As shown in Figure 1, with a 20 min gradient at 60° C from 18-28% acetonitrile modified with 0.1% formic acid, the main peak of eledoisin was separated from six impurity peaks. For users with UNIFI Scientific Information System, data can be

exported as .raw file and processed using MassLynx in conjunction with ProMass HR.




Figure 1. Separation of Eledoisin with Xevo G2-XS QTof MS detection. Detected impurities were annotated as 1–6. Inserted figure shows the sequence and target info column in MassLynx Software where to input the peptide information in MassLynx Software for ProMass HR deconvolution.

For MassLynx Software, data acquisition and processing can be performed on MassLynx integrated with ProMass HR as described previously.³ Briefly, this process includes inputting target information in MassLynx (Figure 1), setting up the ProMass Bridge Parameter file, and entering unnatural or modified amino acids in the ProMass Parameter file. In addition, to fully utilize the resolving power of a Xevo G2-XS, a universal PPL (positive probability ltd) method for synthetic peptides was created in ProMass HR to enable deisotoping of high resolution mass spectra, noise removal, and charge deconvolution. The impurity profiling results were summarized in a report page generated by ProMass HR (Figure 2). As shown in the target summary table, the target peptide eledoisin was successfully identified in the chromatogram with a mass accuracy of 2.4 ppm. Information such as target peptide confirmation, impurity identification, purity assessment, deconvoluted MS spectra, and peak reports can be accessed via hyperlinks or summarized in a report format demonstrating ProMass HR, when used in conjunction with MassLynx, offers high throughput characterization and monitoring of synthetic peptide impurities.

				Target N	lass Sum	mary						
RT (min)	Target Mass Observed (Da) (Da			Mass E	rror I	ntensity	% Abundance (in Spectrum)	%Purit (Estimat		entity	Resul Code	
12.20	1187.6012 1187.60		604	4 0.0028 Da (2.4 ppm)		.78E+008	56.06	54.85		arget Mass		
			S	equence l	Ladder Su	ummary						
RT (min)	Calculated Mass (Da)		Observed Mass (Da)		ss (Da)	Mass Error		Intensity		Sequence		
12.20	1187.6012			1187.604		0.0028 Da (2.4 ppm)		5.788	5.78E+008		/pyr/1-M11	
11.60	566.2	566.2701		566.275		0.0049 Da (8.7 ppm)		4.498	4.49E+003 S		-F7	
13.89	431.2569			431.257		0.0001 Da (0.2 ppm)		4.32E	4.32E+003 I8-		M11	
RT (min)	The state of the s	Base Peak Mass (Da)		Intensity Spectral (rea LC				
3.23	1 1203.		5.83E+				3.71E+004		0.31			
11.27	2 1312.	576	1.95E+	1.95E+005 o		9.59E+004			0.80			
11.60	3 565.2	283	2.04E+	2.04E+005 ok		2.62E+004			0.22			
11.91	4 1116.548		4.61E+	4.61E+005 ol		3.81E+004			0.32			
12.20 Eledoisin1187.604		5.78E+008		ok	1.17E+007		97.85					
12.91	1 5 1100.576		2.30E+005		ok	2.20E+004		0.18				
13.89	6 1188.	574	4.10E+	.10E+005 ok		3.78E+004			0.32			
Mass Peak	List Sorted }											
	+- Std. Der		ensity	Score	Delta I					ed Ide		
Mass(Da)		2.30	E+005	5.36	0.0		100.00	5.79	1187	.6012	(Minus	
1100.576	0.004		FLOOR									
	0.004	2.12	E+005 E+005	5.33	-0.0 88.0			5.12				

Figure 2. ProMass HR impurity profiling reports, including summary tables and peak report. Summary tables listed calculated and observed target mass, mass accuracy, MS and LC purity, detected impurities with color-coded entries hyperlinked (blue text) to further details, such as ESI and Deconvoluted MS Spectra, and deconvolution peak report. Truncated sequences are listed in the Sequence Ladder Summary table while other impurities with presumed identity are listed in the Chromatogram Summary table. The mass tolerance was set at 10 ppm for all possible impurity assignments.

Conclusion

This work demonstrates a high throughput LC-UV/HRMS workflow for synthetic peptide mass confirmation and impurity profiling using a Xevo G2-XS QTof MS with UNIFI or MassLynx and ProMass HR. Retention time, mass, and presumed identity of both the target peptide and impurities were summarized in reports generated by ProMass HR. To this end, the developed workflow can be used for high-resolution synthetic peptide impurity profiling in pharmaceutical developments.

References

- 1. Ott, P. A., et al. An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma, *Nature*, 2017, doi:10.1038/nature22991.
- 2. Shion, H., et al. Developing a Novel, Integrated LC-MS Workflow for High-Resolution Monitoring and Characterization of Oligonucleotides, 720005821EN, Nov 2016.
- 3. Zhang, X., et al. LC-UV-MS-based Synthetic Peptide Identification and Impurity Profiling Using the ACQUITY QDa Detector with ProMass Software, 720005921EN, Feb 2017.

Featured Products

MassLynx MS Software https://www.waters.com/513662

ACQUITY UPLC H-Class PLUS Bio System https://www.waters.com/10166246

Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry https://www.waters.com/134798222

ACQUITY UPLC Tunable UV Detector https://www.waters.com/514228

UNIFI Scientific Information System https://www.waters.com/134801359

720006104, October 2017

©2019 Waters Corporation. All Rights Reserved.